Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.

Reddy, S M; Kopetz, S; Morris, J; Parikh, N; Qiao, W; Overman, M J; Fogelman, D; Shureiqi, I; Jacobs, C; Malik, Z; Jimenez, C A; Wolff, R A; Abbruzzese, J L; Gallick, G; Eng, C

Reddy, S M; Kopetz, S; Morris, J; Parikh, N; Qiao, W; Overman, M J; Fogelman, D; Shureiqi, I; Jacobs, C; Malik, Z; Jimenez, C A; Wolff, R A; Abbruzzese, J L; Gallick, G; Eng, C.

Affiliation

Reddy SM; Hematology-Oncology Fellow, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 463, Houston, TX, 77030, USA, smreddy1@mdanderson.org.

Invest New Drugs ; 33(4): 977-84, 2015 Aug.

Article in En | MEDLINE | ID: mdl-26062928

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Colorectal Neoplasms / Adenocarcinoma / Protein Kinase Inhibitors / Benzodioxoles / Antineoplastic Agents Type of study: Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2015 Document type: Article Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google